GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 116
- Registration Number
- NCT01702480
- Locations
- π¬π§
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 40
- Registration Number
- NCT01702519
- Locations
- πΊπΈ
Celerion NEBRASKA, Lincoln, Nebraska, United States
Nicotine Mouth Film for Craving Relief.
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 320
- Registration Number
- NCT01702532
- Locations
- πΊπΈ
Central Kentucky Research Associates, Inc., Lexington, Kentucky, United States
πΊπΈLos Angeles Clinical Trials, Burbank, California, United States
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 27
- Registration Number
- NCT01702467
- Locations
- π¦πΊ
GSK Investigational Site, Randwick, New South Wales, Australia
A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01702350
- Locations
- π¦πΊ
GSK Investigational Site, Adelaide, South Australia, Australia
This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.
- Conditions
- Obstetric Labour, Premature
- Interventions
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 52
- Registration Number
- NCT01702376
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
- Conditions
- MumpsRubellaMeasles
- Interventions
- Biological: PriorixBiological: M-M-R IIBiological: VarivaxBiological: HavrixBiological: Prevnar 13
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 5016
- Registration Number
- NCT01702428
- Locations
- πͺπΈ
GSK Investigational Site, Valencia, Spain
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345
- Conditions
- Influenza
- Interventions
- Biological: Fluarix Quadrivalent
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 470
- Registration Number
- NCT01702454
- Locations
- π¬π§
GSK Investigational Site, Southampton, United Kingdom
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT01696604
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01691872
- Locations
- π―π΅
GSK Investigational Site, Kagoshima, Japan